Ivosidenib vs Olutasidenib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Acute Myeloid Leukemia

Shared mechanism: Mutant IDH1 · full Acute Myeloid Leukemia pipeline

Ivosidenib · Tibsovo

Marketed by Servier and partners

Approved in Acute Myeloid Leukemiasmall molecule
Reliable signal

NCT03173248 · Phase 3 · active, not recruiting

Participants were randomly assigned 1:1 and participants, care providers and investigators were masked, with a placebo plus azacitidine comparator. The study enrolled 146 people, which is modest, but the primary endpoint, event-free survival, favored ivosidenib with a hazard ratio of 0.33 (95% CI 0.16 to 0.69, p=0.0011), so it was met.

Next expected readout: December 2026 · NCT02074839 (registry estimate)

Reported efficacy

Event-Free Survival (EFS) (Up to Week 24): Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis) (met)

Result source: NCT03173248

Olutasidenib

Marketed by Rigel Pharmaceuticals and partners

Approved in Acute Myeloid Leukemiasmall molecule
Weak signal

NCT02719574 · Phase 1/2 · completed

This is a single-arm, open-label study with no randomization, no blinding, and no comparator or control arm, and it is not an extension of a prior randomized trial. All enrolled patients received olutasidenib (alone or with azacitidine/cytarabine), and the Phase 2 primary endpoints are descriptive response/remission rates rather than comparisons against a control. Because there is no control group, the results cannot separate drug effect from natural history or patient selection, so the evidence is weak regardless of the reported response rates.

Next expected readout: January 2027 · NCT07411586 (registry estimate)

Reported efficacy

Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Phase 1: From start of drug administration (Day 1) up to 28 days after last dose of study drug (up to 82 months)); Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values (Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)); Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG) (Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)); Phase 2, Cohort 1: Percentage of Participants With Complete Remission (CR) Plus Complete Remission With Partial Hematological Recovery (CRh) for Acute Myeloid Leukemia Assessed by Investigator Based on International Working Group (IWG) Response Criteria (Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)); Phase 2, Cohort 3, 4, 5, 6, 7, 8: Percentage of Participants With CR Plus CRh for Acute Myeloid Leukemia Assessed by Investigator Based on IWG Response Criteria (Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)); Phase 2, Cohort 4 and 5: Percentage of Participants With CR for MDS Assessed by IWG Response Criteria (Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)); Phase 2, Cohort 2: Four-month Relapse Free Survival (RFS) Rate (Phase 2: From the date of first dose until relapse or death from any cause, whichever occurs first (up to 4 months)): Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Phase 1: From start of drug administration (Day 1) up to 28 days after last dose of study drug (up to 82 months)): Phase 1: FT-2102 (Single Agent) — TEAEs: 16 Participants; SAEs: 10 Participants | Phase 1: Total FT-2102 (Single Agent) — TEAEs: 31 Participants; SAEs: 23 Participants | Phase 1: FT-2102 + Azacitidine (Combination Therapy) — TEAEs: 39 Participants; SAEs: 30 Participants | Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) — TEAEs: 46 Participants; SAEs: 36 Participants (not_applicable)

Result source: NCT02719574

Results for Acute Myeloid Leukemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIvosidenibOlutasidenib
OS, median—Trial running · NCT0301399811.6bn 153NCT02719574
6 other results
Complete remission—Trial running · NCT03013998—Not reported
Event-free survival, median0.0 vs 0.0±0 vs placebon 72NCT031732485.5bn 153NCT02719574
7 other results
Duration of response, median—Trial running · NCT0301399814.8bn 75NCT02719574
7 other results

OS, median

Ivosidenib
—Trial running · NCT03013998
Olutasidenib
11.6bn 153NCT02719574
6 other results

Complete remission

Ivosidenib
—Trial running · NCT03013998
Olutasidenib
—Not reported

Event-free survival, median

Ivosidenib
0.0 vs 0.0±0 vs placebon 72NCT03173248
Olutasidenib
5.5bn 153NCT02719574
7 other results

Duration of response, median

Ivosidenib
—Trial running · NCT03013998
Olutasidenib
14.8bn 75NCT02719574
7 other results
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ivosidenib: 2 of 4 rows · Olutasidenib: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIvosidenibOlutasidenib
Dropout rate
n/a: no completion milestone
NCT03173248 · Phase 3 · combination · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
—Phase 1: FT-2102 (Single Agent)a
NCT02719574 · Phase 1/2
show 9 more results
—Phase 1: FT-2102 + Azacitidine (Co
NCT02719574 · Phase 1/2 · combination
—Phase 2: Cohort 1; FT-2102 (Single
NCT02719574 · Phase 1/2
—Phase 2: Cohort 2; FT-2102 (Single
NCT02719574 · Phase 1/2
—Phase 2: Cohort 3; FT-2102 (Single
NCT02719574 · Phase 1/2
—Phase 2: Cohort 4; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · combination
—Phase 2: Cohort 5; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · combination
—Phase 2: Cohort 6; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · combination
—Phase 2: Cohort 7; FT-2102 (Single
NCT02719574 · Phase 1/2
—Phase 2: Cohort 8; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · combination
Discontinued due to AEs
—
NCT03173248 · Phase 3 · combination · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
—Phase 1: FT-2102 (Single Agent)a
NCT02719574 · Phase 1/2
show 9 more results
—Phase 1: FT-2102 + Azacitidine (Co
NCT02719574 · Phase 1/2 · combination
—Phase 2: Cohort 1; FT-2102 (Single
NCT02719574 · Phase 1/2
—Phase 2: Cohort 2; FT-2102 (Single
NCT02719574 · Phase 1/2
—Phase 2: Cohort 3; FT-2102 (Single
NCT02719574 · Phase 1/2
—Phase 2: Cohort 4; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · combination
—Phase 2: Cohort 5; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · combination
—Phase 2: Cohort 6; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · combination
—Phase 2: Cohort 7; FT-2102 (Single
NCT02719574 · Phase 1/2
—Phase 2: Cohort 8; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · combination
Serious AEs
69%
NCT03173248 · Phase 3 · combination · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
62.5%Phase 1: FT-2102 (Single Agent)a
NCT02719574 · Phase 1/2
show 9 more results
76.9%Phase 1: FT-2102 + Azacitidine (Co
NCT02719574 · Phase 1/2 · combination
75.2%Phase 2: Cohort 1; FT-2102 (Single
NCT02719574 · Phase 1/2
33.3%Phase 2: Cohort 2; FT-2102 (Single
NCT02719574 · Phase 1/2
80%Phase 2: Cohort 3; FT-2102 (Single
NCT02719574 · Phase 1/2
60%Phase 2: Cohort 4; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · combination
85.7%Phase 2: Cohort 5; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · combination
65%Phase 2: Cohort 6; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · combination
80%Phase 2: Cohort 7; FT-2102 (Single
NCT02719574 · Phase 1/2
81.8%Phase 2: Cohort 8; FT-2102 + Azaci
NCT02719574 · Phase 1/2 · combination
Most frequent reported AEs
nausea 42.3% (placebo 38.4%)
vomiting 39.4% (placebo 26%)
diarrhoea 35.2% (placebo 34.2%)
NCT03173248 · Phase 3 · combination · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
a
fatigue 37.5%
nausea 37.5%
diarrhoea 31.3%
NCT02719574 · Phase 1/2
show 9 more results
nausea 66.7%
constipation 61.5%
platelet count decreased 46.2%
NCT02719574 · Phase 1/2 · combination
nausea 38.6%
constipation 26.8%
red blood cell count decreased 26.1%
NCT02719574 · Phase 1/2
fatigue 33.3%
headache 33.3%
nausea 27.8%
NCT02719574 · Phase 1/2
hypokalaemia 60%
nausea 60%
abdominal pain 40%
NCT02719574 · Phase 1/2
nausea 55%
vomiting 50%
red blood cell count decreased 35%
NCT02719574 · Phase 1/2 · combination
nausea 42.9%
platelet count decreased 42.9%
constipation 33.3%
NCT02719574 · Phase 1/2 · combination
constipation 50%
nausea 40%
fatigue 35%
NCT02719574 · Phase 1/2 · combination
oedema peripheral 50%
cough 40%
decreased appetite 30%
NCT02719574 · Phase 1/2
nausea 72.7%
constipation 63.6%
asthenia 36.4%
NCT02719574 · Phase 1/2 · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ivosidenib

Event-Free Survival 0.03 vs 0.03 placebo months
time to event · months
NCT03173248 · Phase 3 · combination · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3

Olutasidenib

CR/CRh 35% (n=147)
responder rate · % of participants
No placebo or comparator arm
NCT02719574 · Phase 1/2
show 6 more results
0% (n=5)
NCT02719574 · Phase 1/2
47% (n=19)
NCT02719574 · Phase 1/2 · combination
38% (n=13)
NCT02719574 · Phase 1/2 · combination
30% (n=20)
NCT02719574 · Phase 1/2 · combination
40% (n=10)
NCT02719574 · Phase 1/2
45% (n=11)
NCT02719574 · Phase 1/2 · combination
Relapse-free Survival 83% (n=18) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT02719574 · Phase 1/2
Time to Response 1.9 months
time to event · months
No placebo or comparator arm
NCT02719574 · Phase 1/2
show 7 more results
1.9 months
NCT02719574 · Phase 1/2 · combination
1.9 months
NCT02719574 · Phase 1/2
1.8 months
NCT02719574 · Phase 1/2 · combination
2.5 months
NCT02719574 · Phase 1/2 · combination
2.5 months
NCT02719574 · Phase 1/2 · combination
1.9 months
NCT02719574 · Phase 1/2
2.8 months
NCT02719574 · Phase 1/2 · combination
Duration of Response 3.6 months
time to event · months
No placebo or comparator arm
NCT02719574 · Phase 1/2
show 7 more results
22 months
NCT02719574 · Phase 1/2 · combination
14.8 months
NCT02719574 · Phase 1/2
20 months
NCT02719574 · Phase 1/2 · combination
7.25 months
NCT02719574 · Phase 1/2 · combination
4.65 months
NCT02719574 · Phase 1/2 · combination
10.6 months
NCT02719574 · Phase 1/2
20.9 months
NCT02719574 · Phase 1/2 · combination
Relapse-free Survival 18.4 months
time to event · months
No placebo or comparator arm
NCT02719574 · Phase 1/2
Overall Survival 11.6 months
time to event · months
No placebo or comparator arm
NCT02719574 · Phase 1/2
show 7 more results
NA months
NCT02719574 · Phase 1/2
1.2 months
NCT02719574 · Phase 1/2
25.2 months
NCT02719574 · Phase 1/2 · combination
11.6 months
NCT02719574 · Phase 1/2 · combination
10.2 months
NCT02719574 · Phase 1/2 · combination
14 months
NCT02719574 · Phase 1/2
18.7 months
NCT02719574 · Phase 1/2 · combination
Event-Free Survival 5.5 months
time to event · months
No placebo or comparator arm
NCT02719574 · Phase 1/2
show 7 more results
18.4 months
NCT02719574 · Phase 1/2
1.05 months
NCT02719574 · Phase 1/2
5.7 months
NCT02719574 · Phase 1/2 · combination
7.8 months
NCT02719574 · Phase 1/2 · combination
4.8 months
NCT02719574 · Phase 1/2 · combination
5.5 months
NCT02719574 · Phase 1/2
8.1 months
NCT02719574 · Phase 1/2 · combination
Transfusion Independence 47.1% (n=153)
event count · % of participants
No placebo or comparator arm
NCT02719574 · Phase 1/2 · converted to % from 72 Participants as posted
show 7 more results
83.3% (n=18)*
NCT02719574 · Phase 1/2 · converted to % from 15 Participants as posted
0% (n=5)*
NCT02719574 · Phase 1/2 · converted to % from 0 Participants as posted
60% (n=20)*
NCT02719574 · Phase 1/2 · combination · converted to % from 12 Participants as posted
61.9% (n=21)*
NCT02719574 · Phase 1/2 · combination · converted to % from 13 Participants as posted
70% (n=20)*
NCT02719574 · Phase 1/2 · combination · converted to % from 14 Participants as posted
30% (n=10)*
NCT02719574 · Phase 1/2 · converted to % from 3 Participants as posted
72.7% (n=11)*
NCT02719574 · Phase 1/2 · combination · converted to % from 8 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ivosidenib's landscape · Olutasidenib's landscape